Tag: opioid use disorder

📉 Overdose Deaths in the U.S. Dropped Nearly 27% in 2024 – A Sign of Hope 🇺🇸

📉 Overdose Deaths in the U.S. Dropped Nearly 27% in 2024 – A Sign of Hope 🇺🇸

According to newly released CDC data, the U.S. experienced a nearly 27% decline in overdose deaths last year — the first major drop in over five years. While the crisis is far from over, this marks a critical turning point and a reason for cautious optimism.

Key contributors to this progress include:

✅ Expansion of harm reduction strategies

✅ Increased access to naloxone and medications for opioid use disorder

✅ Shifts in drug supply dynamics and targeted public health interventions

As someone on the front lines caring for patients every day, I’ve witnessed firsthand the devastating toll of opioid addiction. I’ve lost patients to this crisis — and I’ve also seen close friends and family fight their way back from the brink. Their recovery wouldn’t have been possible without access to critical resources, especially life-saving medications and sustained support.

This progress didn’t happen by chance — it’s the result of continued investment in prevention, treatment, and recovery. We cannot afford to lose momentum now. If anything, this is the moment to double down.

Let’s keep the pressure on. Reach out to your representatives. Push for increased funding. Our collective commitment has brought us this far — now let’s go even further. Lives depend on it.

Let’s build on this progress with compassion, science, and unwavering commitment.

0

The Twin Epidemic: Rising Co-Prescriptions of Opioids and Stimulants in the U.S.

A recent 10-year longitudinal cohort study has unveiled concerning trends in the co-prescription of opioids and stimulants, shedding light on the escalating “twin epidemic” in the United States.

Key Findings:

  • Prevalence of Co-Prescription: Approximately 5.5% of patients received both opioid and stimulant prescriptions during the study period. 
  • Increased Opioid Dosage: Patients co-prescribed stimulants were more likely to escalate their opioid doses over time, with the highest doses observed in the South and West regions.
  • Associated Conditions: Common diagnoses among these patients included depression, anxiety, attention-deficit/hyperactivity disorder (ADHD), and chronic pain

Implications:

The concurrent use of opioids and stimulants poses significant risks, including increased chances of overdose, cardiovascular events, and mental health complications. This study emphasizes the need for healthcare providers to carefully consider the implications of co-prescribing these medications and to monitor patients closely.

Call to Action:

It’s crucial to raise awareness about this emerging twin epidemic. Healthcare professionals, policymakers, and patients must collaborate to develop strategies that mitigate risks associated with co-prescriptions and ensure safer prescribing practices.

0

Buprenorphine vs. Methadone: The Battle for Opioid Use Disorder Treatment Supremacy

A recent study in JAMA compared the effectiveness of buprenorphine/naloxone versus methadone for opioid use disorder (OUD), focusing on treatment retention and mortality outcomes. The findings highlight important differences in these two mainstay treatments:

  1. Treatment Retention: Methadone demonstrated significantly higher retention rates compared to buprenorphine/naloxone. Retention is a critical metric, as staying in treatment reduces the risk of relapse and overdose. In flexible-dose studies, buprenorphine/naloxone patients were 37–40% more likely to discontinue treatment than methadone recipients. This aligns with its pharmacological profile, as methadone provides more consistent suppression of withdrawal symptoms.
  2. Mortality Rates: There were no significant differences in mortality risks between the two treatments, indicating both are comparably safe when provided in a supervised setting.
  3. Dosing Implications: Higher doses of buprenorphine (≥16 mg/day) were associated with better retention and reduced emergency care visits, suggesting dose adequacy is vital in achieving optimal outcomes. However, underdosing or rigid dosing protocols may limit buprenorphine’s effectiveness in real-world settings.
  4. Practical Considerations: Methadone requires daily visits to specialized clinics, which can be a barrier to care for some patients. In contrast, buprenorphine/naloxone can often be prescribed in primary care settings, improving accessibility.

The choice between methadone and buprenorphine/naloxone should be individualized, considering patient preferences, clinical circumstances, and potential barriers to adherence. These findings underscore the need for flexible treatment options tailored to the patient population.

0

Buprenorphine and Psychosis: Unraveling the Risks of Abrupt Discontinuation

This post is inspired by a real case from my practice involving a patient with no significant past psychiatric history but a strong history of substance use, including opioids and cocaine. The patient had been on buprenorphine maintenance therapy for several decades, providing stability in their recovery. However, following an abrupt discontinuation of buprenorphine, the patient developed acute psychotic symptoms. This case highlights an uncommon but important phenomenon clinicians should be aware of when managing buprenorphine discontinuation, especially in individuals with a history of substance use.

Emerging evidence suggests that abrupt discontinuation of buprenorphine may induce psychosis in some individuals, though this appears to be a relatively uncommon occurrence.

Documented Cases

  • New-onset psychotic symptoms have been reported after sudden cessation of buprenorphine in patients with no prior psychosis.
  • Common symptoms include auditory hallucinations, paranoid ideation, and delusions of reference.
  • Psychotic symptoms typically emerge within days to weeks after discontinuation.

Potential Mechanisms

  1. Loss of buprenorphine’s antipsychotic effects through kappa-opioid receptor antagonism.
  2. Interaction between neurobiological vulnerabilities and the stress of withdrawal.
  3. Possible unmasking of latent psychotic disorders.

Risk Factors

  • History of substance use.
  • Early adverse life events.
  • Underlying psychiatric conditions (e.g., bipolar disorder).

Outcomes and Management

  • Symptoms may resolve in weeks to months, though some cases persist longer.
  • Reintroduction of buprenorphine has led to symptom remission in some cases, suggesting a causal relationship.
  • Gradual tapering of buprenorphine might mitigate this risk, though more research is needed.

Clinical Implications

Clinicians should remain vigilant when discontinuing buprenorphine, especially in individuals with risk factors for psychosis. A gradual tapering strategy is recommended to reduce potential risks, though further studies are necessary to guide best practices.

Understanding this phenomenon highlights the importance of individualized care when managing buprenorphine discontinuation in vulnerable populations.

0

Abrupt Discontinuation of Buprenorphine and Risk of Psychosis: Clinical Considerations

This post is inspired by a real case from my practice involving a patient with no significant past psychiatric history but a strong history of substance use, including opioids and cocaine. The patient had been on buprenorphine maintenance therapy for several decades, providing stability in their recovery. However, following an abrupt discontinuation of buprenorphine, the patient developed acute psychotic symptoms. This case highlights an uncommon but important phenomenon clinicians should be aware of when managing buprenorphine discontinuation, especially in individuals with a history of substance use.

Emerging evidence suggests that abrupt discontinuation of buprenorphine may induce psychosis in some individuals, though this appears to be a relatively uncommon occurrence. Here are the key findings:

Documented Cases

  • New-onset psychotic symptoms have been reported after sudden cessation of buprenorphine in patients with no prior psychosis.
  • Common symptoms include auditory hallucinations, paranoid ideation, and delusions of reference.
  • Psychotic symptoms typically emerge within days to weeks after discontinuation.

Potential Mechanisms

  1. Loss of buprenorphine’s antipsychotic effects through kappa-opioid receptor antagonism.
  2. Interaction between neurobiological vulnerabilities and the stress of withdrawal.
  3. Possible unmasking of latent psychotic disorders.

Risk Factors

  • History of substance use.
  • Early adverse life events.
  • Underlying psychiatric conditions (e.g., bipolar disorder).

Outcomes and Management

  • Symptoms may resolve in weeks to months, though some cases persist longer.
  • Reintroduction of buprenorphine has led to symptom remission in some cases, suggesting a causal relationship.
  • Gradual tapering of buprenorphine might mitigate this risk, though more research is needed.

Clinical Implications

Clinicians should remain vigilant when discontinuing buprenorphine, especially in individuals with risk factors for psychosis. A gradual tapering strategy is recommended to reduce potential risks, though further studies are necessary to guide best practices.

Understanding this phenomenon highlights the importance of individualized care when managing buprenorphine discontinuation in vulnerable populations.

0

Locked Out: Why Most Inmates Are Denied Life-Saving Opioid Treatment

The JAMA Network Open article titled “Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails” investigates the availability of medications for opioid use disorder (MOUD) in U.S. jails, such as methadone, buprenorphine, and naltrexone. It highlights that MOUD, which is a critical component in treating opioid use disorder (OUD), is underutilized in correctional facilities, despite its effectiveness in reducing overdose rates, withdrawal symptoms, and recidivism.

Key factors influencing MOUD availability in jails include jail size, regional location, the political landscape, and resources available in the facility. Jails in larger urban areas or those in states with Medicaid expansion are more likely to provide MOUD. Barriers such as stigma, lack of funding, and inadequate healthcare infrastructure also limit access to these medications.

The study emphasizes the importance of expanding access to MOUD in jails to address the opioid epidemic and improve public health outcomes for incarcerated populations as only 44% of jails offer MOUD in the current system. 

0

Be Cautious with Gabapentin in Patients on MAT for Opioid Use Disorder 

In my practice, I frequently see patients on Medication-Assisted Treatment (MAT) for opioid use disorder, whether it’s Suboxone or methadone, also being prescribed high-dose gabapentin—often without a clear indication for its use. This raises some serious red flags. ⚠️

While gabapentin can be useful in certain situations, we know there’s an increased risk of overdose when it’s combined with opioids, especially in those with a history of opioid use disorder. Gabapentin can suppress the central nervous system, making it more dangerous in combination with other sedating medications.

If there’s no solid reason for the prescription, it’s best to steer clear. Always prioritize safety and question if gabapentin is truly necessary in these cases. Let’s keep patient care and harm reduction at the forefront.

💡 Key takeaway: If there’s no clear indication, think twice before prescribing gabapentin to someone on MAT. Their safety depends on it.

0

Want to Live Longer with a Serious Mental Health Condition? Say No to Alcohol, Drugs, and Smoking!

The article “Major Psychiatric Disorders, Substance Use Behaviors, and Longevity” explores the complex relationships between psychiatric disorders, substance use, and life expectancy. The authors examine how conditions like schizophrenia, bipolar disorder, and major depression affect longevity, often leading to reduced lifespans. This is largely due to increased risk factors, such as poor physical health, unhealthy lifestyles, and increased rates of suicide.

Substance use behaviors, including alcohol, tobacco, and drug use, often co-occur with psychiatric disorders, compounding the negative effects on longevity. The article emphasizes the need for better integration of mental health and substance use treatment into healthcare systems. It also advocates for targeted interventions to reduce mortality rates, improve the quality of life, and enhance access to comprehensive care for individuals with psychiatric disorders.

Link to the article: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2820199

0

U.S. Overdose Deaths Hit Historic Low: A Turning Point in the Opioid Crisis

A recent NPR exclusive reveals a significant and unexpected decline in U.S. overdose deaths, marking the first drop in decades. Data from the Centers for Disease Control and Prevention (CDC) shows a nationwide reduction of roughly 10.6% in overdose deaths. Some states with rapid data collection have seen declines as high as 20-30%, suggesting the possibility of saving up to 20,000 lives annually.

This turnaround follows years of increasing fatalities, largely driven by fentanyl and other synthetic opioids. Experts credit the broader availability of life-saving treatments, such as naloxone, and improvements in support systems for people at risk of overdosing. While the overall number of overdose deaths remains high, many in the public health community are cautiously optimistic, believing the worst of the crisis might be over for now

0

Rethinking the Concept of Addiction: Beyond the Brain Disease Model

When it comes to treating addiction, the prevailing idea is that it’s simply a chronic brain disease. But in reality, few experts fully subscribe to this view in isolation. We understand that not everyone who uses drugs, alcohol, or gambles ends up with a life-destroying addiction. Many individuals manage to engage with substances or behaviors without it overtaking their lives—they maintain jobs, care for their families, and function in society. This suggests that addiction is much more than a biological condition; it’s an intricate interplay of biology, social influences, environmental factors, and personal choices.

It’s worth pausing to consider what labeling addiction as a chronic disease implies. On one hand, it suggests that even if you strive for change, addiction remains a lingering presence—one that can pull you back into destructive patterns at any moment. This can foster a disheartening and pessimistic outlook, as it positions addiction as an inescapable burden. The concept of a chronic disease also reinforces the idea that ongoing, lifelong treatment is necessary, often with medications like buprenorphine, which may be prescribed for years, or even indefinitely, to prevent relapse.

While I absolutely recognize the biological underpinnings of addiction and the life-saving role medications like buprenorphine play, we must look beyond just biology to truly understand and address addiction. The motivations behind substance use and the social contexts in which it occurs are equally important. Humanity’s long history of seeking altered states of consciousness suggests that drug use is often a response to emotional pain or difficult circumstances. People frequently use substances as an escape, and understanding these personal and social factors is key to effective treatment.

At its core, successful addiction therapy must focus on uncovering the reasons behind substance use and helping individuals develop healthier coping strategies. Treatment that focuses solely on the biological side—without considering the psychological and social aspects—often falls short. It’s critical to provide not just medical interventions but also hope and optimism, which are fundamental to any healing process. Addiction may not be a simple choice, but it certainly involves choices, and it emerges from a complex web of circumstances in a person’s life.

In the end, we should avoid oversimplifying addiction as merely a chronic brain disease. True treatment requires a holistic approach, considering all the elements—biological, social, environmental, and personal—that create the conditions for addiction to thrive. Only then can we offer meaningful, lasting solutions for those struggling with addiction.

Link to the article:

0

Powered by WordPress.com.

Up ↑